PROCEPT BioRobotics Corporation Stock News

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.63 per share a year ago.

SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing t

PROCEPT BioRobotics Corporation (PRCT) Q4 2023 Earnings Call Transcript

Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.

SAN JOSE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative

PROCEPT BioRobotics Corporation (PRCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving high

The mean of analysts' price targets for PROCEPT BioRobotics Corporation (PRCT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong

PROCEPT BioRobotics Corporation (PRCT) Q3 2023 Earnings Call Transcript

With the innovation sector moving at full speed, it's time for investors to consider the best tech stocks to buy now but not necessarily for the reason you might assume. Yes, the exchange-traded fund

SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing tr

REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transforma

PRCT's aquablation therapy has shown strong growth, with revenues of $57.5mm in Q2 FY'23. The company's economic levers include new system placements, and growth from its installed base, with a record

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.43 per share a year ago.

REDWOOD CITY, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developin

Procept had weak results on adding fewer than expected Aquabeam devices in Q1 of 2023, leading to a fall in the shares. Procept has strong potential in urology where its Aquablation technology has man